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years of age (  = –0.12, t = –2.37, p = 0.018), but positively with 
FSS in adults aged  1 52 years (  = 0.13, t = 2.51, p = 0.012). 
Longitudinal analysis demonstrated a similar pattern.  Con-
clusions: Decreased cardiac vagal activity is associated with 
a higher number of FSS in adults aged  ^  52 years in the gen-
eral population. The unexpected association between in-
creased cardiac vagal activity and FSS in adults aged  1 52 
years needs further exploration. The role of age should be 
acknowledged in future studies on ANS function in the etiol-
ogy of FSS.  Copyright © 2010 S. Karger AG, Basel 
 Introduction 
 It has been widely accepted that functional somatic 
symptoms (FSS), that is, physical complaints not ex-
plained by underlying organic pathology, have a multi-
factorial etiology with numerous contributing factors of 
biological, psychological, and social origin  [1–4] . Al-
though psychosocial stress is widely regarded as an im-
portant etiological factor  [1] , it is largely unknown how 
increased levels of psychosocial stress contribute to the 
experience of FSS. Dysfunction of the autonomic nervous 
system (ANS), a stress-responsive system, is an interest-
ing underlying mechanism to consider  [5] .
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 Abstract 
 Background: Functional somatic symptoms (FSS) are symp-
toms not explained by underlying organic pathology. It has 
frequently been suggested that dysfunction of the auto-
nomic nervous system (ANS) contributes to the develop-
ment of FSS. We hypothesized that decreased cardiac vagal 
activity is cross-sectionally and prospectively associated 
with the number of FSS in the general population.  Methods: 
This study was performed in a population-based cohort of 
774 adults (45.1% male, mean age  8 SD 53.5  8 10.7 years). 
Participants completed the somatization section of the 
Composite International Diagnostic Interview surveying the 
presence of 43 FSS. ANS function was assessed by spectral 
analysis of heart rate variability in the high-frequency band 
(HRV-HF), reflecting cardiac vagal activity. Follow-up mea-
surements of HRV-HF and FSS were performed approximate-
ly 2 years later.  Results: Linear regression analyses, with ad-
justments for gender, age, body mass index, anxiety, de-
pression, smoking, alcohol use, and frequency of exercise, 
revealed an interaction of cardiac vagal activity with age: 
HRV-HF was negatively associated with FSS in adults  ^  52 
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 The ANS is influenced by acute, repetitive, and chron-
ic psychosocial stress  [6–8] . When the load of stressors in 
an individual is too large or when the ANS is chronically 
addressed, eventually ANS dysfunction may develop  [9] . 
Given the vital role of the ANS in the regulation of bodi-
ly organs function, increased sympathetic activity or de-
creased parasympathetic activity may contribute to pe-
ripheral somatosensory arousal and experience of FSS 
 [10–12] . Although ANS dysfunction seems a plausible 
mechanism to mediate the association between psycho-
social stress and FSS, an alternative pathway is also pos-
sible. In this alternative pathway, ANS dysfunction may 
be a consequence or epiphenomenon of FSS, driven by 
factors such as medication use, psychiatric comorbidity, 
or lifestyle factors  [13] . A widely used proxy for ANS 
function is heart rate variability (HRV), reflecting inter-
beat interval fluctuations in heart rate. HRV indices have 
been particularly used to assess cardiac vagal activity as 
reflected in the high-frequency band (HRV-HF)  [14] .
 ANS function has never been studied in relation to FSS 
in the general population. However, cardiac vagal activ-
ity has been studied in patients with functional somatic 
disorders (FSD), which are clusters of related FSS. Exam-
ples of FSD are chronic fatigue syndrome, fibromyalgia, 
and irritable bowel syndrome. A recent meta-analysis of 
those three FSD indicated statistically significant lower 
cardiac vagal activity in FSD patients compared to con-
trols  [15] , with no apparent differences between chronic 
fatigue syndrome, fibromyalgia, and irritable bowel syn-
drome. The validity of those summary estimates was, 
however, significantly limited by unexplained heteroge-
neity in the included studies. Furthermore, when taking 
the presence of potential publication bias into account, 
the difference in cardiac vagal activity between FSD pa-
tients and controls disappeared. These results suggest 
that some studies contrasting with the prevailing beliefs 
on lowered cardiac vagal activity in FSD have not been 
published. In addition, a structured review revealed sub-
stantial room for improvement in methodological qual-
ity, especially regarding adjustment for po tential con-
founders. Furthermore, important potential moderators 
have not been taken into account. Only few studies have 
examined the associations of cardiac vagal activity and 
FSS according to gender  [16, 17] and none has examined 
the associations according to age. Especially age may be 
an important moderator, as recently illustrated by a study 
on HRV and depression. While cardiac vagal activity 
generally decreases with increasing age  [18] , this study 
observed that cardiac vagal activity remained stable with 
increasing age in depressed patients but not in controls 
 [19] . Finally, no longitudinal studies have been published 
exploring the issue whether ANS alterations precede de-
velopment of FSS or FSD. All taken together, the current 
knowledge on the role of the ANS in FSS is inconclusive 
and requires further study.
 The purpose of the present study was to investigate the 
role of ANS function in FSS in a large population-based 
cohort of adults, taking the role of potential confounders 
and moderators into account. We hypothesized that de-
creased cardiac vagal activity is cross-sectionally associ-
ated with FSS in the general population. In addition, we 
hypothesized that age moderated the association between 
cardiac vagal activity and FSS, in the sense that the asso-
ciation would be stronger in younger than in older adults. 
Additionally, we hypothesized that cardiac vagal activity 
is not differentially related to different bodily clusters of 
FSS. Furthermore, we hypothesized that decreased car-
diac vagal activity predicts development of FSS in a 2-year 
follow-up period.
Subjects and Methods  
 Population 
 Our study was performed in a cohort derived from the Preven-
tion   of Renal and Vascular End-Stage Disease (PREVEND), a ma-
jor population-based cohort study investigating microalbumin-
uria as a risk factor for renal and cardiovascular disease. The re-
cruitment of participants for the PREVEND study has been 
extensively described elsewhere  [20, 21] . The PREVEND study 
population (n = 8,592) was enriched for albuminuria, which was 
rectified in the current substudy in order to obtain a population-
representative study sample. Research assistants handed over in-
vitations to 2,554 subjects to participate in the current substudy 
for which additional psychiatric and psychosocial data were col-
lected during two measurement waves. Baseline measurements in 
the 2001–2002 wave were completed by a total of 1,094 partici-
pants (43%), forming our study cohort. PREVEND participants 
who declined to participate in the current study did not signifi-
cantly differ from those who did participate concerning gender, 
age, or neuroticism score  [22] . Follow-up measurements in the 
2003–2004 wave were completed by a total of 976 participants 
(89%). Dropout participants (n = 118) were older (mean age  8 SD 
56.6  8 11.9 vs. 52.7  8 11.2 years, t = 3.66, p  ! 0.01) and more of-
ten female (66 vs. 52%,   2 = 8.13, p  ! 0.01), but did not differ sig-
nificantly in baseline number of FSS or in neuroticism score. The 
study was approved by the local medical ethics committee. All 
subjects gave written consent to participate in the study.
 Functional Somatic Symptoms 
 FSS were measured by the somatization section of the Com-
posite International Diagnostic Interview (CIDI), as extensively 
described previously  [21] . The CIDI has adequate test-retest reli-
ability and validity  [23] . Participants first completed the CIDI 
lifetime version measuring lifetime FSS. A total of 1,088 complet-
ed CIDIs were available at baseline. Two years later, participants 
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were reinterviewed and completed the CIDI 12-month version, in 
which the occurrence of the 43 symptoms in the previous year is 
surveyed; 964 completed CIDIs were available at follow-up. In our 
main analyses, we use the sum of all FSS in the CIDI 12-month 
version, henceforth defined as FSS. New-onset FSS were identi-
fied comparing the FSS reported in the CIDI 12-month version 
with those reported in the lifetime interview.
 Additionally, we constructed bodily clusters of FSS, based on 
symptom clusters previously identified in a large study on the 
classification of FSS  [24] . We defined a cardiopulmonary factor 
(chest pain and shortness of breath), a musculoskeletal factor 
(back pain, joint pain, pain in extremities, loss of touch or pain 
sensation, muscle weakness, and numbness or tingling sensa-
tions), a gastrointestinal factor (abdominal pain, nausea, diar-
rhea, feeling bloated or flatulence, and food intolerance), and a 
general symptoms factor (headache, trouble with balance and 
walking, dizziness). A dichotomous score for every bodily system 
symptom cluster was calculated (0 = no FSS in specific symptom 
cluster, 1 = one or more FSS in specific symptom cluster).
 Cardiovascular Measures 
 Both at baseline and follow-up, HRV was measured with par-
ticipants lying on a bench in the supine position in a quiet labora-
tory room, breathing spontaneously. Because of the circadian 
rhythm of cardiac vagal activity  [25] , timing of HRV measure-
ments was standardized in the afternoon. Research assistants 
who measured HRV were blinded to our study hypotheses. There 
were no restrictions in eating, drinking, or smoking in the hours 
prior to the measurement. Participants were encouraged to relax 
and asked not to move or speak during data acquisition. A prerest 
period of 10 min in the supine position was applied before the 
HRV measurement started. A cuff was fixed around the middle 
phalanx of the third finger on the right hand. A Portapres device 
(FMS Finapres Medical Systems BV, Amsterdam, The Nether-
lands) continuously recorded heart rate during 10 min. Segments 
with a duration of approximately 300 s were selected for spectral 
analysis. In case there was no appropriate segment of 300 s, blocks 
of 60–300 s were selected  [26] . Beat-to-beat variation measure-
ments provided by the Finapres are almost interchangeable with 
electrocardiogram in the resting supine position  [27] . Power spec-
tral analysis of heart rate signals was performed with the CARS-
PAN software program  [28] . The measurements were checked on 
stationarity and corrected for artifacts. Artifacts were eliminated 
and the resulting gaps were linearly interpolated. When contain-
ing more than 10% interpolated heart rate intervals or too many 
artifacts, the data were considered unstable and discarded. Par-
ticipants for whom no reliable HRV measurement was available 
( ! 5% at both measurement waves) were comparable to partici-
pants with reliable HRV measurements regarding sex, age, and 
number of FSS. The high-frequency band (HRV-HF), defined at 
0.15–0.40 Hz, is expressed in milliseconds squared and mainly 
reflects cardiac vagal activity  [14, 26] . After natural logarithm (ln) 
transformation, HRV-HF values are expressed in ln (ms 2 ). Sys-
tolic blood pressure (BP) and diastolic BP were measured on two 
occasions in the supine position on the right arm every minute for 
10 min with an automatic Dinamap XL model 9300 series moni-
tor (Johnson-Johnson Medical Inc., Tampa, Fla., USA). BP (in 
mm Hg) was calculated as the mean of the last two measurements 
at both occasions.
 Statistical Analysis 
 Analyses were performed using the Statistical Package for So-
cial Sciences version 15.0 (SPSS Inc., Chicago, Ill., USA). Given the 
skewed distribution, the number of FSS and new-onset FSS were 
log-transformed (after transformation, skewness = 0.92, kur-
tosis = 0.14). Extreme values ( 1 3 SD) of HRV-HF (n = 6 at base-
line, n = 12 at follow-up) were excluded. We also excluded par-
ticipants using antihypertensives (  -blockers, angiotensin-con-
verting enzyme inhibitors, and angiotensin receptor blockers 
assessed by self-report, n = 140 at baseline, n = 165 at follow-up), 
because these medications exert effects on HRV  [29] . Multivari-
able linear regression analyses were used to assess the indepen-
dent effect of HRV-HF on the number of FSS in both the cross-
sectional and longitudinal analyses, and additionally on the new-
onset FSS analysis (model 1). Interaction terms were created from 
the centered variables to avoid problems with multicollinearity 
(model 2). In case of statistically significant interactions, strati-
fied analyses are presented (model 3). Standardized   values are 
given. Additionally, we applied multivariable logistic regression 
analyses to test the effect of HRV-HF on the odds of having FSS 
in a specific bodily system cluster. Odds ratios (OR) and 95% con-
fidence intervals (95% CI) are presented. All regression analyses 
were adjusted for gender, age, body mass index, anxiety and de-
pressive disorder (DSM-IV diagnoses as assessed by CIDI), smok-
ing, alcohol use, and frequency of exercise, since these may be 
responsible for variance in ANS function  [30–34] and FSS  [35–
40] . Furthermore, interactions of both age and gender with HRV-
HF (HRV-HF  ! age, HRV-HF  ! gender) were tested because we 
expected that the extent to which ANS dysfunction contributes to 
FSS might vary between age and gender groups  [17, 41] . Longitu-
dinal analyses were additionally adjusted for the number of life-
time FSS at baseline. All analyses were also performed after sec-
ondary exclusion of participants having self-reported cardiovas-
cular disease or using antidepressant medication (nonselective 
monoamine reuptake inhibitors, selective serotonin reuptake in-
hibitors, and monoamine oxidase inhibitors) derived from the In-
terAction database containing pharmacy dispensing data  [42] .
All p values  ! 0.05 were considered statistically significant.
 Results 
 General Characteristics 
 Table 1 shows the general characteristics of our final 
study population (n = 774). The distribution of the total 
number of FSS is positively skewed; the median number 
of FSS was 1 (interquartile range 0–2). The most com-
monly reported FSS was headache (10.7%); other preva-
lent FSS were joint pain (10.6%) and back pain (9.4%).
 Cross-Sectional Analysis of HRV-HF and FSS 
 Cross-sectional results from multivariable linear re-
gression analyses are presented in  table 2 . In model 1, 
HRV-HF is not associated with the number of FSS. After 
entering interaction terms HRV-HF  ! age and HRV-HF 
 ! gender in model 2, a significant interaction between 
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HRV-HF and age emerges, indicating that the association 
between HRV-HF and the number of FSS changes with 
increasing age. Model 3 presents a stratified analysis 
based on a median split of the modifying variable age. 
This stratification reveals that HRV-HF is inversely and 
significantly associated with FSS in adults aged  ^  52 
years (  = –0.12, t = –2.37, p = 0.018), whereas HRV-HF 
is positively and significantly associated with FSS in 
adults aged  1 52 years (  = 0.13, t = 2.51, p = 0.012). Ad-
ditionally, we calculated the coefficients of HRV-HF in 
explaining the number of FSS in 5 age categories, dem-
onstrating that this interaction effect is linear (age  ! 45 
years,   = –0.19, t = –2.24, p = 0.027; age 45–50 years,
  = –0.07, t = –0.96, p = 0.339; age 51–55 years,   = 0.00, 
t = 0.01, p = 0.996; age 56–60 years,   = 0.09, t = 0.99,
p = 0.324; age  1 60 years,   = 0.15, t = 2.08, p = 0.039). In 
 table 1 , the general characteristics of the two age groups 
based on the median split are shown.
 Cross-Sectional Analysis of HRV-HF and Bodily 
Clusters of FSS 
 Next, we examined whether the association between 
HRV-HF and FSS was the same in different bodily clus-
ters. Due to the low number of participants having FSS 







Age (mean 8 SD), years 53.5810.7 45.284.8 62.587.7
Female, % 54.9 56.1 53.6
Body mass index (mean 8 SD) 25.983.8 25.683.9 26.383.6
Smoking, %
No smoking 79.6 75.7 83.8
1–5 cigarette(s)/day 2.7 3.2 2.2
6–10 cigarettes/day 4.3 5.0 3.5
11–15 cigarettes/day 6.2 7.9 4.3
16–20 cigarettes/day 5.0 5.5 4.6
>20 cigarettes/day 2.2 2.7 1.6
Alcohol use, %
No alcohol use 20.2 17.6 22.9
1–4 unit(s)/month 16.4 15.1 17.8
2–7 units/week 33.2 39.7 26.1
1–3 unit(s)/day 27.5 25.3 29.9
>4 units/day 2.7 2.2 3.2
Frequency of exercise, %
Not/hardly 49.5 43.4 58.4
Once per week 29.9 28.3 21.6
Twice or more per week 20.6 28.3 20.0
Antidepressant use, % 2.3 2.0 2.7
Depressive disorder (DSM-IV), % 6.7 7.7 5.7
Anxiety disorder (DSM-IV), % 5.7 6.4 4.7
Number of FSS (median) 
Number of FSS 1 (0–2) 1 (0–2) 1 (0–2)
Number of new-onset FSS 0 (0–1) 0 (0–1) 0 (0–1)
Number of lifetime FSS 3 (1–5) 3 (1–5) 2 (1–4)
Heart rate (mean 8 SD), beats/min 69810 68810 69811
SBP (mean 8 SD), mm Hg 122816 118813 127818
DBP (mean 8 SD), mm Hg 7288 7088 7389
HRV-HF
ms2 (median) 466 (216–973) 645 (322–1,170) 314 (162–665)
ln ms2 (mean 8 SD) 6.1581.28 6.4481.22 5.8581.28
DBP = Diastolic blood pressure; DSM-IV = Diagnostic and Statistical Manual of Mental Disorders, fourth 
edition; SBP = systolic blood pressure. Figures in parentheses indicate interquartile ranges.
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in the cardiorespiratory bodily cluster (n = 41), this clus-
ter was excluded for multivariable logistic regression. 
Similar to the cross-sectional analyses with the total 
number of FSS, for all clusters borderline statistically 
significant HRV-HF  ! age interaction effects were ob-
served. The OR for HRV-HF  ! age for the 3 bodily 
symptom clusters followed the same pattern and mag-
nitude: HRV-HF  ! age predicted FSS in the musculo-
skeletal factor (OR = 1.18, 95% CI = 0.98–1.42, z = 3.06, 
p = 0.080), gastrointestinal factor (OR = 1.21, 95% CI = 
0.96–1.54, z = 2.58, p = 0.108), and general symptoms 
factor (OR = 1.22, 95% CI = 0.99–1.51, z = 3.32, p = 
0.069).
 Longitudinal Analysis of HRV-HF and FSS 
 In the longitudinal analysis, a similar pattern as found 
in the cross-sectional analysis emerged for the relation 
between HRV-HF and FSS (see  table 3 for an overview). 
In model 1, HRV-HF at baseline does not predict the 
number of FSS at follow-up approximately 2 years later. 
In model 2, the interaction term HRV-HF  ! age is sta-
tistically significant (  = 0.07, t = 1.97, p = 0.049). After 
stratification in two age groups based on a median split, 
the   values follow the same pattern as in the cross-sec-
tional analyses, however, HRV-HF does not significantly 
predict FSS in any of those subgroups. Additionally, when 
only considering new-onset FSS, i.e. FSS that were only 
reported in the 12-month interview performed at follow-
up but not in the lifetime interview performed at base-
line, essentially the same pattern emerged (data not 
shown).
 All analyses were also performed after secondary ex-
clusion of participants having cardiovascular disease or 
using antidepressant medication. These secondary anal-
yses did not essentially change the results; therefore, only 
results of the total sample are shown for maximal gener-
alizability.
 Discussion 
 The aim of this study was to investigate the relation 
between ANS dysfunction and FSS in a general popula-
tion-based cohort. As hypothesized, lower HRV-HF, 
which indicates decreased cardiac vagal activity, was as-
sociated with the number of FSS in adults aged  ^  52 years. 
In contrast, in adults aged  1 52 years, higher HRV-HF
was associated with the number of FSS. The same pat-
tern, although not statistically significant in all analyses, 
emerged in the prospective part of our study when pre-
dicting FSS at 2-year follow-up.
 This is the first study to report on the relationship be-
tween ANS function and FSS in a population-based co-
hort adjusted for a large range of confounders. In adults 
Table 2. Coefficients from multivariable linear regression models predicting the number of FSS out of HRV-HF and possible con-
founders: cross-sectional analysis









 p value  p value  p value  p value
HRV-HF 0.00 0.923     –0.02 0.620     –0.11 0.018* 0.13 0.012*
Female gender 0.18 <0.001* 0.19 <0.001* 0.19 <0.001* 0.22 <0.001*
Age 0.02 0.592 0.02 0.557 0.03 0.512 0.06 0.271
Body mass index 0.07 0.051 0.06 0.073 0.11 0.024* 0.00 0.993
Anxiety 0.21 <0.001* 0.21 <0.001* 0.18 <0.001* 0.31 <0.001*
Depression 0.11 0.003* 0.11 0.004* 0.19 <0.001*     –0.03 0.600
Smoking 0.07 0.052 0.07 0.066 0.06 0.208 0.04 0.439
Alcohol                                   –0.09 0.015*     –0.08 0.024*     –0.19 <0.001* 0.06 0.259
Frequency of exercise            –0.01 0.737     –0.01 0.853     –0.02 0.691     –0.03 0.564
HRV-HF ! age 0.10 0.004*
HRV-HF ! gender     –0.04 0.286
R2 0.14 0.15 0.22 0.14
* p < 0.05. Model 3 is based on a median split of the moderating variable age.
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aged  ^  52 years, our results are in agreement with previ-
ous findings of lower HRV-HF at rest in patients with 
FSD in a meta-analysis  [15] . Although the reliability of 
the summary estimate in this meta-analysis was affected 
by poor quality of underlying studies, heterogeneity, and 
potential publication bias, the present study supports the 
finding of lower HRV-HF in persons with FSS. This as-
sociation was the same for males and females. As hypoth-
esized, we have demonstrated that general, musculoskel-
etal, and gastrointestinal FSS bodily clusters share a com-
parable association with HRV-HF.
 Unexpectedly, as high cardiac vagal activity should 
protect against the sensation of FSS according to our hy-
pothesis, we have demonstrated a significant association 
between higher cardiac vagal activity and the number of 
FSS in adults aged  1 52 years, which remained after exclu-
sion of participants with cardiovascular disease. Given 
the current lack of similar research in this age group, we 
can only speculate about reasons for the positive associa-
tion between HRV-HF and FSS in adults  1 52 years old.
 First, etiological factors in the development of FSS may 
differ between younger and older persons  [43] , which 
may also apply to the role of stress-responsive systems. In 
the current study, explained variance in FSS is 20% in 
adults aged  ^  52 years in contrast to only 14% in adults 
 1 52 years of age. For example, in keeping with our re-
sults, it has been found that depressive disorder is not as-
sociated with FSS in older adults  [44] . However, age dif-
ferences in etiological factors do not specifically explain 
the  positive direction of the association with HRV-HF 
and FSS in adults aged  1 52 years.
 Second, HRV-HF decreases with increasing age and 
has been associated with several diseases of aging, includ-
ing obesity, diabetes mellitus, and hypertension  [45] , 
making it difficult to distinguish low HRV related to dis-
ease from normal aging. Also, variance in HRV-HF in-
creases and reliability decreases with increasing age  [46] . 
This may indicate that high HRV values reflect different 
physiological processes in younger persons than in older 
persons  [47] . Indeed, it has been reported that not only 
low HRV, as repeatedly found in previous population-
based cohort studies, but also high HRV is a prognostic 
factor for cardiovascular mortality in the elderly  [48] . Au-
thors ascribe this remarkable finding to an increased 
prevalence of sinus node dysfunction causing higher 
HRV. However, excluding participants with cardiovascu-
lar comorbidity from our study sample did not essential-
ly change the results. An unanticipated interaction be-
tween age and HRV-HF in psychophysiological research 
has been shown before, in a study examining HRV-HF 
Table 3. Coefficients from multivariable linear regression models predicting the number of FSS out of HRV-HF and possible confound-
ers: longitudinal analysis









 p value  p value  p value  p value
HRV-HF 0.03 0.413 0.02 0.640      –0.02 0.704 0.07 0.143
Female gender 0.07 0.052 0.07 0.033* 0.10 0.049* 0.05 0.332
Age 0.09 0.006* 0.09 0.007* 0.07 0.158 0.09 0.070
Body mass index 0.04 0.240 0.04 0.232 0.08 0.100 0.01 0.845
Anxiety 0.09 0.014* 0.09 0.014* 0.11 0.028* 0.05 0.308
Depression 0.05 0.143 0.05 0.138 0.15 0.003*     –0.07 0.160
Smoking 0.05 0.143 0.05 0.163 0.04 0.358 0.04 0.450
Alcohol                                   –0.02 0.527      –0.02 0.555      –0.09 0.052 0.06 0.233
Frequency of exercise 0.00 0.965 0.00 0.967      –0.04 0.447 0.04 0.434
Lifetime FSS 0.50 <0.001* 0.50 <0.001* 0.43 <0.001* 0.56 <0.001*
HRV-HF ! age 0.07 0.049*
HRV-HF ! gender 0.03 0.375
R2 0.32 0.32 0.35 0.34
* p < 0.05. Model 3 is based on a median split of the moderating variable age.
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and depression in the elderly. As expected, increasing age 
was associated with decreased HRV-HF in healthy con-
trols, however, the depressed group did not show an as-
sociation between age and HRV-HF  [19] . In this study, 
inspection of regression lines suggests that between-
group differences might be evident before age 60, but not 
thereafter. This cutoff seems to be in line with the age-as-
sociated differences in the association between HRV-HF 
and FSS in the present study.
 Third, sensitivity to painful stimuli correlates in-
versely with BP levels, possibly due to baroreflex-medi-
ated inhibition of pain transmission at both spinal and 
supraspinal levels, a process known as hypertension-
associated hypalgesia  [49] . The prevalence of hyperten-
sion, which is characterized by lower cardiac vagal ac-
tivity, is higher in older adults  [29] . Therefore, hyperten-
sion-associated hypalgesia would be consistent with our 
finding of a positive association between HRV-HF and 
FSS in adults aged  1 52 years. However, only a minority 
of the FSS concern pain symptoms. In addition, post hoc 
tests taking BP into account as a possible confounder
in the current study did not significantly attenuate the 
positive association between HRV-HF and FSS in adults 
aged  1 52 years.
 All taken together, a comprehensive explanation for 
the association between increased HRV-HF and FSS in 
older age groups appears not readily available. This in-
triguing finding warrants further research.
 The current study is the first to present prospective 
data on ANS function and FSS. It can be argued that al-
terations in cardiac vagal activity do not cause FSS, but 
are instead a consequence or epiphenomenon. In that 
case, ANS alterations are due to lifestyle factors such as 
physical inactivity, smoking and alcohol use, medica-
tion use, or psychiatric comorbidity  [13] . However, 
HRV-HF was still independently associated with FSS in 
our analyses taking those factors into account. Longitu-
dinal analyses, examining whether lowered cardiac va-
gal activity predicts development of FSS, yielded essen-
tially the same results as the cross-sectional part of the 
study. Of note, prospective associations were weaker 
and not always statistically significant. As results in our 
longitudinal analyses are not conclusive, this associa-
tion may be better studied in populations at risk for FSS 
and FSD.
 Some limitations of this study should be taken into ac-
count.
First, the number of FSS in the CIDI was measured by 
retrospective self-report. Nevertheless, we are confident 
that we were able to identify FSS using the CIDI, since as-
sociations with important characteristics like gender, de-
pression, and anxiety were similar to previous studies on 
the prevalence of FSS in the general population  [50] and 
in primary care  [51] in which a medical doctor was di-
rectly involved.
 Second, three remarks regarding our measurement of 
HRV should be taken into account. Although recom-
mended as a quality criterion  [15] , we did not give restric-
tions in eating, drinking or smoking in the hours before 
the HRV measurements. However, we do not think this 
has influenced our results substantially, since we adjusted 
the analyses for smoking and alcohol use. Furthermore, 
we used BP fluctuations as determined by the Finapres 
finger cuff to detect the occurrence of a heart beat. Al-
though the distal pulse wave is almost interchangeable 
with an electrocardiogram  [27] , it may be argued that the 
use of an electrocardiogram may be preferable, especial-
ly when participants with different ages are included as 
arterial stiffness and thereby pulse transit time is influ-
enced by age. However, it has been shown that pulse pres-
sure is not independently associated with HRV after con-
trolling for age and gender. Therefore, we do not think 
that measuring heart rate peripherally has influenced our 
findings  [52] .  Third, we did not measure respiratory rate 
and depth, while it has been recommended that respira-
tion frequency needs to be monitored and adjusted for to 
generate an accurate measure of HRV-HF. However, this 
requirement seems particularly relevant when studying 
within-subject HRV measurements  [53] , whereas correc-
tion or control procedures are discouraged in between-
subject design such as in our study, since HRV-HF seems 
not dependent on respiration frequency under baseline 
conditions  [54] .
Finally, we did not measure some factors that may fur-
ther characterize the type of somatization, such as pre-
cipitating psychological events or demoralization  [5] , and 
may influence its association with cardiac vagal activity.
 Among the strengths of this study are the large sample 
size and the extensive data collection allowing for adjust-
ment of potential confounders and detecting gender- and 
age-dependent effects, which has been an area of weak-
ness in previous research. In addition, our longitudinal 
data on ANS dysfunction in relation to FSS are unique 
and enabled us to study the direction of effects.
 In conclusion, decreased cardiac vagal activity ap-
peared to be associated with FSS in adults aged  ^  52 years 
in the general population. Unexpectedly, higher cardiac 
vagal activity was associated with FSS in adults aged  1 52 
years, a finding that needs replication and better under-
standing. Further prospective studies investigating the 
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role of the ANS in FSS, acknowledging the role of age, are 
required to make a next step in clarifying the role of ANS 
dysfunction in the etiology of FSS.
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